Karen L. Seeberger

Karen L. Seeberger

Auto-generated profile, based on publicly available information

Karen L. Seeberger

Department of Surgery, University of Alberta, Edmonton, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2021 in Xenotransplantation
Verified
Journal Article
Closed access
PDF file
JBJessie M. Barra
Jessie M. Barra
VKVeronika Kozlovskaya
Veronika Kozlovskaya
JKJessica D. Kepple
Jessica D. Kepple
KSKaren L. Seeberger
Karen L. Seeberger
PKPurushothaman Kuppan
Purushothaman Kuppan
HTHubert Tse
Hubert Tse

8 April 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SASaloni Aggarwal
Saloni Aggarwal
NCNerea Cuesta-Gomez
Nerea Cuesta-Gomez
JPJoy Paramor
Joy Paramor
SKSandra Kelly
Sandra Kelly
KPKateryna Polishevska
Kateryna Polishevska
APAndrew R Pepper
Andrew R Pepper
Islet transplantation (ITx) has demonstrated that cellular therapies can improve glycemic control in patients with type 1 diabetes. However, cell death in the acute post-transplant period accounts for the loss of up to 70% of the islets, resulting in the requirement of multiple donors per recipient to achieve normoglycemia. Several studies have targeted apoptosis prevention after ITx; herein, our study explores a novel approach by modulating RIPK1-associated stress pathways using Necrostatin-1 (Nec-1) to enhance human islet survival, engraftment, and function post-transplant. Nec-1 treatment for 24 h prior to transplant significantly reduced the expression of RIPK1 ( p = 0.0021) and RIPK3 ( p = 0.0042), resulting in decreased cell death ( p < 0.0001) and necroptosis ( p < 0.0001), measured as TUNEL + and pMLKL + cells, respectively, without affecting basal respiration or insulin secretion in human islets. Nec-1 treatment pre-transplant drastically reduced cytokine ( p = 0.0083), NFκB ( p = 0.0179), TGFβ ( p = 0.0015) and TNF family ( p = 0.0010) signaling pathways at the transcriptional level compared to control. These results correlated with increased diabetes reversal ( p = 0.0200) and decreased reversal time ( p = 0.0011) in the Nec-1-treated group compared to untreated controls. The success of Nec-1 treatment in this study showcases that short-term modulation of RIPK1-associated stress pathways promotes early human marginal mass engraftment post-ITx. In the clinical context, improvement of marginal mass islet function could enable single-donor islet infusion and could aid in future ß-cell replacement therapies, making ITx available to a broader population of individuals living with diabetes.